Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Benitec Biopharma Inc.NASDAQ: BNTC
Total Equity · Q3 FY2026 · quarter ended Mar 2026
Total equity rises 87.9% from a year ago
Total equity stood at $183.33M at the end of Q3 FY2026, up 87.9% from a year earlier and down 2.2% from the prior quarter. Over 3 fiscal years it compounded at +223.2% a year.
Context
- Total equity amounted to 98.0% of total assets at the end of Q3 FY2026, up 5.3 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +87.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 97.3M USD
- Year-over-year change
- +105.9%
- 4-year CAGR
- +48.5%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 97.3M | +105.9% |
| FY2024 | 2024-06-30 | 47.25M | +23290.1% |
| FY2023 | 2023-06-30 | 202K | -93.0% |
| FY2022 | 2022-06-30 | 2.88M | -85.6% |
| FY2021 | 2021-06-30 | 20.01M | — |
Total Equity vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 total equity of $183.33M is the 5th highest of the 10 companies compared; the peer median is $112.9M.
- Its year-over-year change of +87.9% is the highest of 10, against a peer median of -18.7%.
- Total equity amounts to 98.0% of total assets for BNTC, versus a peer median of 57.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $374.13M | +27.1% | -5.3% | 88.5% | |
| Dec 2025 | $305.68M | -25.1% | -17.7% | 57.2% | |
| Mar 2026 | $237.78M | -18.5% | +39.0% | 90.4% | |
| Mar 2026 | $200.74M | -18.7% | -15.0% | 94.1% | |
| Mar 2026 | $183.33M | +87.9% | +223.2% | 98.0% | |
| Mar 2026 | $112.9M | +33.4% | -5.7% | 41.5% | |
| Mar 2026 | $108.83M | -70.7% | -15.8% | 20.6% | |
| Mar 2026 | $52.7M | -32.1% | -15.5% | 48.1% | |
| Mar 2026 | $5.81M | -63.5% | — | 10.2% | |
| Mar 2026 | -$130.24M | -16.0% | — | 826.4% | |
| Peer median (excluding BNTC) | $112.9M | -18.7% | -15.0% | 57.2% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.